Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis-Reference-Cited by-同舟云学术

Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis

Published:2017-09-01 Issue: Volume: Page:
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:
Short-container-title:Exp Ther Med

Author:

Liu Yuanyuan¹,Zhang Yu²,Feng Gangling¹,Niu Qiang¹,Xu Shangzhi¹,Yan Yizhong¹,Li Shugang¹,Jing Mingxia¹

Affiliation:

1. Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China

2. Department of Obstetrics and Gynecology, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quercetin Promotes Apoptosis of Gastric Cancer Cells through the EGFR-ERK Signaling Pathway;Journal of Food Biochemistry;2024-02-13

2. Surface-Modified Biobased Polymeric Nanoparticles for Dual Delivery of Doxorubicin and Gefitinib in Glioma Cell Lines;ACS Omega;2023-07-26

3. Beyond traditional therapy: Mucoadhesive polymers as a new frontier in oral cancer management;Biopolymers;2023-06-21

4. Potential of Heterocyclic Compounds as EGFR-TK Inhibitors in Cancer Therapy;Novel Technologies in Biosystems, Biomedical & Drug Delivery;2023

5. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials;Medicine;2022-12-02